Why buprenorphine is so successful in treating opiate addiction in France.
Why buprenorphine is so successful in treating opiate addiction in France.
复制标题
DOI：
10.1007/s11920-007-0046-2
复制
发表时间：
2007-10-01
影响因子：
6.7
通讯作者：
Auriacombe, Marc
中科院分区：
文献类型：
--
作者：
Fatseas, M;Auriacombe, Marc
在法国，自1995年以来，所有注册医生都被允许在没有任何特殊教育或许可证的情况下开丁丙诺啡。这导致在初级保健中接受丁丙诺啡治疗的阿片剂依赖者人数迅速增加。法国的医生补偿机制、药房服务和医疗保险资金都有助于尽量减少丁丙诺啡治疗的障碍。在法国，大约20%的医生开丁丙诺啡治疗估计18万问题海洛因使用者中的一半以上。高达20%的丁丙诺啡患者可能发生丁丙诺啡静脉转移，导致与镇静剂联合用药时相对罕见的过量，而阿片类药物过量死亡总数大幅下降。在法国，在宽松的监管环境下，通过办公室处方对问题阿片剂使用者进行丁丙诺啡维持治疗是可行和安全的。
In France, all registered medical doctors have been allowed to prescribe buprenorphine without any special education or licensing since 1995. This has led to a rapidly increasing number of opiate-dependent users under buprenorphine treatment in primary care. French physician compensation mechanisms, pharmacy services, and medical insurance funding all have contributed to minimizing barriers to buprenorphine treatment. Approximately 20% of all physicians in France are prescribing buprenorphine to treat more than one half of the estimated 180,000 problem heroin users. Intravenous diversion of buprenorphine may occur in up to 20% of buprenorphine patients and has led to relatively rare overdoses in combination with sedatives, whereas total opiate overdose deaths have declined substantially. In France, buprenorphine maintenance treatment for problem opiate users was feasible and safe through office-based prescriptions in a relaxed regulatory environment.